Header Logo

Connection

Prudence Ive to South Africa

This is a "connection" page, showing publications Prudence Ive has written about South Africa.
Connection Strength

0,295
  1. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
    View in: PubMed
    Score: 0,045
  2. Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers. Front Immunol. 2021; 12:781263.
    View in: PubMed
    Score: 0,019
  3. Treatment outcomes among patients admitted to hospital with antiretroviral and/or antituberculosis drug-induced liver injury. S Afr Med J. 2021 Apr 30; 111(5):474-481.
    View in: PubMed
    Score: 0,019
  4. The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study. Int J Infect Dis. 2018 Aug; 73:78-84.
    View in: PubMed
    Score: 0,015
  5. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
    View in: PubMed
    Score: 0,015
  6. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. J Acquir Immune Defic Syndr. 2018 04 01; 77(4):413-416.
    View in: PubMed
    Score: 0,015
  7. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,013
  8. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. Trop Med Int Health. 2016 09; 21(9):1131-7.
    View in: PubMed
    Score: 0,013
  9. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
    View in: PubMed
    Score: 0,012
  10. Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study. BMC Infect Dis. 2015 Jan 13; 15:12.
    View in: PubMed
    Score: 0,012
  11. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
    View in: PubMed
    Score: 0,011
  12. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,011
  13. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
    View in: PubMed
    Score: 0,011
  14. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,010
  15. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,010
  16. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,010
  17. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
    View in: PubMed
    Score: 0,010
  18. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,009
  19. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,009
  20. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,009
  21. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,009
  22. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.